AUTLAutolus Therapeutics plc

Nasdaq autolus.com


$ 4.51 $ -0.18 (-3.94 %)    

Friday, 17-May-2024 14:53:52 EDT
QQQ $ 450.75 $ -1.97 (-0.44 %)
DIA $ 399.07 $ -0.05 (-0.01 %)
SPY $ 528.36 $ -0.57 (-0.11 %)
TLT $ 91.40 $ -0.22 (-0.24 %)
GLD $ 223.69 $ 1.45 (0.65 %)
$ 4.07
$ 4.69
$ 4.49 x 100
$ 0.00 x 0
$ 4.41 - $ 4.75
$ 2.01 - $ 7.45
2,575,944
na
1.08B
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-autolus-therapeutics-maintains-9-price-target

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.

 autolus-therapeutics-q1-eps-024-compared-with-023-yoy-quarterly-sales-totals-1009m-exits-quarter-with-cash--equivalents-worth-7585m

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.24)

 autolus-therapeutics-presents-3-clinical-data-updates-on-obe-cel-in-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia-patients-at-the-2024-eha-congress-june-13-16-2024

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell...

 autolus-therapeutics-delays-its-first-quarter-2024-earnings-release-and-conference-call

The Company is canceling its previously announced earnings release and call scheduled for before U.S. market open on May 14, 20...

 autolus-therapeutics-announces-abstract-for-longer-term-follow-up-and-additional-data-analysis-of-pivotal-phase-2-felix-study-of-obe-cel-for-adult-rr-b-all-selected-for-an-oral-presentation-at-asco

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell...

 needham-reiterates-buy-on-autolus-therapeutics-maintains-9-price-target

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.

 truist-securities-maintains-buy-on-autolus-therapeutics-raises-price-target-to-11

Truist Securities analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from ...

 needham-maintains-buy-on-autolus-therapeutics-maintains-9-price-target

Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION